Table 1.
Overall survival and median survival periods from 6 phase 3 trials in which overall survival was the primary end-point of efficacy.
| YEAR | DRUG | ECOG-PERFORMANCE STATUS | CHILD-PUGH GRADE | OVERALL SURVIVAL (hazard ratio) | MONTHS OF SURVIVAL (median) | LINE OF THERAPY |
|---|---|---|---|---|---|---|
| 2007 | SORAFENIB | ≤ 2 | A | 0.69 (vs.. placebo) | 10.7 vs. 7.9 | 1 |
| 2018 | LENVATINIB | ≤ 1 | A | 0.92 (vs. sorafenib) | 13.6 vs. 12.3 | 1 |
| 2020 | ATEZOLIZUMAB AND BEVACIZUMAB | ≤ 1 | A | 0.58 (vs. sorafenib) | 19.2 vs. 13.4 | 1 |
| 2017 | REGORAFENIB | ≤ 1 | A | 0.63 (vs. placebo) | 10.6 vs. 7.8 | 2 |
| 2019 | RAMUCIRUMAB | ≤ 1 | A | 0.71 (vs. placebo) | 8.5 vs. 7.3 | 2 |
| 2019 | CABOZANTINIB | ≤ 1 | A | 0.76 (vs. placebo) | 10.2 vs. 8.0 | 2 |